Sie suchten nach: alkylating (Maltesisch - Englisch)

alkylating agents
alkylating agents

tmz huwa aġent alkylating embrijotossiku, teratoġeniku, u ġenotossiku.
tmz is an embryotoxic, teratogenic and genotoxic alkylating agent.

aġenti antineoplastiċi – sustanzi alkylating oħra, kodiċi atc l01a x03
l01a x03

kimoterapija preċedenti tkun inkludiet sustanza ta’ antracycline jew alkylating.
previous chemotherapy should have included an anthracycline or an alkylating agent.

pazjenti b’ b- ll li kienu rċevew alkylating agent u
received an alkylating agent and had failed fludarabine

it-terapija preċedenti kellha tinkludi xi anthracycline jew xi sustanza alkylating.
previous chemotherapy should have included an anthracycline or an alkylating agent.

il-perijodu ta’ latency huwa qasir ħafna, anke għal alkylating agent.
this latency period is very short even for an alkylating agent.

dan il- perijodu ta ’ latency huwa qasir ħafna, anke għal sustanza alkylating.
this latency period is very short even for an alkylating agent.

kategorija farmakoterapewtika: sustanzi antineoplastiċi, sustanzi alkylating, sulfonati alkyl, kodiċi atc: lo1ab01
pharmacotherapeutic group: antineoplastic agents, alkylating agents, alkyl sulfonates, atc code: l01ab01.

kategorija farmakoterapewtika: aġenti antineoplastiċi, aġenti alkylating,, kodiċi atc: l01ac01 mekkaniżmu ta’ azzjoni
pharmacotherapeutic group: antineoplastic agents, alkylating agents, atc code: l01ac01 mechanism of action

ir- riskju li wieħed jiżviluppa majelodisplażja jew lewkimja wara l- kura b ’ “ alkylating agents ” hu magħruf sew.
the risk of developing secondary myelodysplasia or leukaemia following therapy with alkylating agents is well known.

ir- riskju ta ’ dawn il- kanċers sekondarji li jseħħu wara terapija b’ sustanzi alkylating hija diġà magħrufa sew mit- tobba.
the risk of these secondary cancers occurring after therapy with alkylating agents is already well- known to doctors.

f’dawk il-pazjenti li kienu ħadu l-kors bis-sustanza alkylating, li falla, docetaxel kien imqabbel ma’ doxorubicin (75 mg/m2 kull 3 ġimgħat).
in alkylating-failure patients, docetaxel was compared to doxorubicin (75 mg/m² every 3 weeks).